Home Featured Page 114

Featured

Latest

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your Truth

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

PT386 – Vital Psychedelic Conversations

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™...

Silo Pharma Announces Expansion of Intellectual Property Portfolio

Ehave Provides Progress Update on its HPPD Study with University of...

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday,...

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding...

The Agenda for Economic Analyses of Psychedelic-assisted Therapy

A Perspective on Providers: Scaling PAT in a Time of Therapist...

Making “Access” A Meaningful Part of Every Conversation about Psychedelic Therapy

Psychedelic Therapies: From Approvals to Access

1...113114115...303 Page 114 of 303

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your...

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your Truth

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

PT386 – Vital Psychedelic Conversations

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™...

Silo Pharma Announces Expansion of Intellectual Property Portfolio

Ehave Provides Progress Update on its HPPD Study with University of...

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday,...

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding...

The Agenda for Economic Analyses of Psychedelic-assisted Therapy

A Perspective on Providers: Scaling PAT in a Time of Therapist...

Making “Access” A Meaningful Part of Every Conversation about Psychedelic Therapy

Psychedelic Therapies: From Approvals to Access

EDITOR PICKS

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your...

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY